GemPharmatech Co., Ltd. Class A
SSSE:68804627.78
CNY
-1.43
(-4.90%)
ISIN
CNE100005964
Return %
Stock
S&P 500
1Y
61.70
14.20
3Y
73.30
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Jing Zhao
- Full Time Employees
- 1,590
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Nanjing China
- IPO Date
- Apr 25, 2022
- Website
- gempharmatech.com
- Similar Companies
- Business
- GemPharmatech Co., Ltd. is a preclinical contract research organization (CRO) and biotechnology enterprise specializing in the research, development, production, and commercialization of genetically engineered animal models and preclinical contract research services. Founded in 2017 and headquartered in Nanjing, China, the company caters to multinational pharmaceutical companies, biotechnology firms, academic research institutes, and clinical research laboratories worldwide. The company operates primarily across laboratory animal model development and preclinical contract research service segments. Its product portfolio features more than 30,000 genetically engineered mouse models, including constitutive knockout and conditional knockout strains established under the Knockout All Project (KOAP); severely immunodeficient mouse lines, led by the proprietary NCG series and its engineered variants such as NCG-M and NCG-X for human stem cell and tissue engraftment; humanized target models, such as immune checkpoint, cytokine, and metabolic humanized mice; disease-specific models spanning oncology, autoimmune diseases, metabolic disorders, neurodegenerative conditions, and rare genetic diseases; germ-free and gnotobiotic strains for microbiome and immunology studies; and wild-derived strains developed under The Wild Mouse Project. GemPharmatech's service portfolio comprises custom animal model generation via CRISPR/Cas9 and embryonic stem cell gene-editing technologies; in vivo pharmacology and drug efficacy testing; pharmacokinetic and pharmacodynamic profiling; comprehensive phenotyping; patient-derived xenograft (PDX) and cell line-derived xenograft (CDX) tumor modeling; high-throughput in vitro and in vivo screening; and auxiliary animal support services, including commercial breeding, cryopreservation, in vitro fertilization, strain rederivation, and animal health quality testing. In recent developments, GemPharmatech expanded its global operational infrastructure by inaugurating an expanded U.S. headquarters featuring a specialized rodent vivarium and laboratory space in San Diego, California, alongside establishing international subsidiaries in South Korea and Hong Kong. In strategic collaborations, the company entered into an alliance with Goodwill E-Health Info Co., Ltd. to construct an artificial intelligence-enhanced PDX model database and multimodal biological computing platform for oncology therapeutic discovery. Additionally, the company launched the NeoMab fully human antibody transgenic mouse platform, established NeoMab Biotechnology (Suzhou), commenced operations at its Guangdong Industrial Park facility, expanded domestic production capacities across Beijing and Shanghai, and obtained Animal Welfare Assurance from the U.S. Office of Laboratory Animal Welfare (OLAW).